APA (7th ed.) Citation

Chae, H., Yoo, C., Yoon, J., Lee, H. J., Kim, K., Kim, J., . . . Kim, S. (2018). FcrR3A -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. Journal of breast cancer, 21(1), 45-50. https://doi.org/10.4048/jbc.2018.21.1.45

Chicago Style (17th ed.) Citation

Chae, Heejung, et al. "FcrR3A -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival Among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment." Journal of Breast Cancer 21, no. 1 (2018): 45-50. https://doi.org/10.4048/jbc.2018.21.1.45.

MLA (9th ed.) Citation

Chae, Heejung, et al. "FcrR3A -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival Among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment." Journal of Breast Cancer, vol. 21, no. 1, 2018, pp. 45-50, https://doi.org/10.4048/jbc.2018.21.1.45.